Monashee Investment Management LLC Purchases Shares of 137,430 Contineum Therapeutics, Inc. $CTNM

Monashee Investment Management LLC purchased a new stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 137,430 shares of the company’s stock, valued at approximately $1,571,000. Monashee Investment Management LLC owned about 0.47% of Contineum Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd purchased a new stake in Contineum Therapeutics during the first quarter valued at about $118,000. Strs Ohio purchased a new stake in Contineum Therapeutics during the first quarter valued at about $27,000. Norges Bank purchased a new stake in Contineum Therapeutics during the second quarter valued at about $674,000. Qube Research & Technologies Ltd purchased a new stake in Contineum Therapeutics during the second quarter valued at about $43,000. Finally, Jane Street Group LLC purchased a new stake in Contineum Therapeutics during the second quarter valued at about $81,000.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CTNM. Wall Street Zen raised shares of Contineum Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Robert W. Baird upped their price objective on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the company an “outperform” rating in a research note on Friday, March 6th. Morgan Stanley upped their price objective on shares of Contineum Therapeutics from $14.00 to $16.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Contineum Therapeutics in a report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Contineum Therapeutics Price Performance

Shares of CTNM opened at $11.86 on Friday. The company has a market capitalization of $443.45 million, a price-to-earnings ratio of -6.08 and a beta of 0.89. Contineum Therapeutics, Inc. has a fifty-two week low of $3.57 and a fifty-two week high of $16.33. The business’s 50-day moving average is $13.13 and its 200-day moving average is $12.94.

Contineum Therapeutics (NASDAQ:CTNM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.16. Equities research analysts expect that Contineum Therapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.